Eyepoint study results for vision treatment disappoint, but company still sees promise
Data could imperil biotech’s plans to seek regulatory approval in competitive field Adobe By Adam Feuerstein Aug. 17, 2026 Adam Feuerstein, a senior writer and biotech columnist, is the. . .
Data could imperil biotech’s plans to seek regulatory approval in competitive fieldAdobeByAdam FeuersteinAug. 17, 2026Adam Feuerstein, a senior writer and biotech columnist, is the author ofAdam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and biotechnology. Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcastThe Readout Loudand author of the newsletterAdam’s Biotech Scorecard. You can reach Adam on Signal at stataf. 54. Eyepoint said Monday that patients administered its experimental treatment for a common cause of age-related blindness failed to maintain vision with less frequent injections compared to a standard treatment — meaning a Phase 3 clinical trial had fallen short of its primary goal. The study setback imperiled Eyepoint’s plans to seek regulatory approval for the drug, Duravyu, and caused its stock price to plummet. Shares of Ocular Therapeutix, the maker of a competing eye treatment that will be submitted to the Food and Drug Administration later this year, rose in reaction. Both Eyepoint and Ocular are developing drugs to maintain vision in people with wet age-related macular degeneration, or wet AMD; those drugs can be injected into the eye less frequently than currently approved treatments. STAT+ Exclusive StoryAlready have an account?Log inThis article is exclusive to STAT+ subscribersUnlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. Already have an account?Log inView All PlansTo read the rest of this story subscribe to STAT+. SubscribeSenior Writer, BiotechAdam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcastThe Readout Loudand author of the newsletterAdam’s Biotech Scorecard. You can reach Adam on Signal at stataf. 54.